The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntelligent Ultrasound Regulatory News (IUG)

Share Price Information for Intelligent Ultrasound (IUG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.00
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 0.50 (6.25%)
Open: 8.25
High: 8.25
Low: 8.25
Prev. Close: 8.25
IUG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of ScanNav FetalCheck and its use in study

23 Nov 2023 07:00

RNS Number : 3853U
Intelligent Ultrasound Group PLC
23 November 2023
 

Intelligent Ultrasound announces launch of new gestational age estimation AI software, ScanNav FetalCheck and its use in first field study

 

PRESS RELEASE 23 November 2023: Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in artificial intelligence (AI) software and simulation, is pleased to announce a new AI development programme for gestational age estimation in prenatal care. ScanNav FetalCheck scanning technology aims to enable a non-skilled or skilled user to establish the gestational age (GA) accurately with minimal training.

 

Pregnant women are usually offered two routine ultrasound scans. The first at 11-14 weeks is performed to confirm viability of the fetus as well as the gestational age to pinpoint the likely due date. A second scan at 18-20 weeks focusses on detecting congenital abnormalities. Additional scans may be offered to monitor high-risk or complex pregnancies.

 

Having an accurate gestational age is important in the management of pregnancy, both to assess fetal growth and to inform treatment choice in the event that complications are seen. However, accurate determination of GA is difficult in low and middle -income countries (LMICs) as, currently, GA must be measured by trained sonographers, and very few front-line healthcare workers have the necessary skills.

 

Intelligent Ultrasound's ScanNav FetalCheck software aims to enable a non-skilled user to get an accurate GA with minimal training and without the need for an expensive high-end ultrasound machine. It has the potential to transform antenatal care both in LMICs and in high income countries (HICs) by allowing the age of the fetus to be assessed in a primary care setting where women need it.

 

Intelligent Ultrasound is also pleased to announce that a leading university in Africa has purchased four ScanNav FetalCheck systems as part of a trial to evaluate biomarkers and other factors which affect the probability of stillbirth.

 

ScanNav FetalCheck is currently not licenced for clinical use.

 

Aris Papageorghiou, Professor of fetal medicine at the University of Oxford said:

"Accurate estimation of gestational age is crucial for prenatal care: all aspects depend on knowledge of how far along the pregnancy journey a woman and her fetus are. In many low-income settings this is just not available, chiefly due to unavailability of expensive ultrasound equipment and trained staff. In this project, hand-held ultrasound and AI technology are being paired to overcome these roadblocks - this is disruptive technology that has the potential to allow better pregnancy care for all women."

 

Nicholas Sleep, COO at Intelligent Ultrasound said:

"The use of ScanNav FetalCheck in this first field study is a testament to the ease of use of our new AI software. Our mission is to make ultrasound easier to learn and simpler to use. This is the next step on our journey to achieving this and putting ultrasound into the hands of front-line health practitioners."

 

ENDS

 

Enquiries:

 

Intelligent Ultrasound Group plc

www.intelligentultrasound.com

Stuart Gall, CEO

Tel: +44 (0)29 2075 6534

Helen Jones, CFO

 

 

Cavendish Securities Plc

(Nominated advisor and broker)

 

Giles Balleny (Corporate Finance)

Nigel Birks (ECM)

Dale Bellis (Sales)

Tel: +44 (0)20 7397 8900

 

 

 

 TB Cardew - PR Advisors

 Ed Orlebar

Intelligentultrasound@tbcardew.com

Tel: +44 (0)7738 724630

 Allison Connolly

Tel: +44 (0)7587 453955

 Emma Pascoe-Watson

Tel: +44 (0)7774 620415

 Jessica Pilling 

Tel: +44 (0)7918 584573

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,500 simulators have been sold to over 750 medical institutions around the world.

 

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE HealthCare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

 

www.intelligentultrasound.com

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA, but is not available for sale in any other territory requiring government approval for this type of product.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLBTBPTMTMTBAJ
12
Date   Source Headline
1st May 20247:00 amRNSFinal Results
19th Apr 20247:00 amRNSSonolyst launched on Voluson Signature Series
19th Apr 20247:00 amRNSNotice of Results
29th Feb 20247:00 amRNSNHS Scotland Adopts Classroom to Clinic Training
27th Feb 20243:45 pmRNSScanNav FetalCheck Used in Trial Study
9th Feb 20247:00 amRNSLaunch of Portable NeedleTrainer Plus
9th Jan 20247:00 amRNSTrading Update
22nd Dec 20237:00 amRNSGrant of Share Options
27th Nov 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
23rd Nov 20237:00 amRNSLaunch of ScanNav FetalCheck and its use in study
17th Nov 20237:00 amRNSSonoLystlive now standard on Voluson Expert Series
7th Nov 20237:00 amRNSIntelligent Ultrasound signs research agreement
11th Sep 20237:00 amRNSSonoLystlive launched on Voluson Expert Series
17th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
24th Jul 20237:00 amRNSTrading Update
21st Jun 20234:08 pmRNSResult of AGM
26th May 20237:00 amRNSDirectorate Change
26th May 20237:00 amRNSNotice of AGM and 2022 Report and Accounts
22nd May 20233:57 pmRNSHolding(s) in Company
18th May 20237:00 amRNSMello investor conference
20th Apr 20233:15 pmRNSHolding(s) in Company
20th Apr 20237:00 amRNSFinal Results
23rd Mar 20234:45 pmRNSPDMR/PCA Dealing
15th Mar 20237:00 amRNSNotice of Results
16th Jan 20237:00 amRNSTrading update
8th Dec 20227:00 amRNSSupport programme in improving global healthcare
30th Nov 20221:12 pmRNSResult of GM
11th Nov 20227:00 amRNSPlacing and Subscription to raise £5.2 million
20th Oct 20227:00 amRNSScanNav Anatomy PNB clearance for sale in the USA
19th Oct 20222:05 pmRNSSecond Price Monitoring Extn
19th Oct 20222:00 pmRNSPrice Monitoring Extension
23rd Sep 20227:00 amRNSChange of Auditor
2nd Sep 202211:09 amRNSLaunch of NeedleTrainer 2
18th Aug 20227:00 amRNSHalf-year Report
15th Aug 20227:00 amRNSDirectorate Change
8th Aug 20227:00 amRNSNotice of Results
21st Jul 20227:00 amRNSTrading update
20th Jul 20227:00 amRNSAI technology incorporated into Voluson Expert 22
22nd Jun 202212:08 pmRNSResult of AGM
22nd Jun 20227:00 amRNSAGM Statement
21st Jun 202211:05 amRNSHolding(s) in Company
30th May 20227:00 amRNSNotice of AGM and 2021 Report and Accounts
3rd May 20227:00 amRNSFinal Results
28th Apr 20227:00 amRNSInvestor presentation
25th Apr 20227:00 amRNSNotice of Results
25th Jan 20227:00 amRNSAdditional product agreement with GE Healthcare
13th Jan 20228:12 amRNS2021 Full Year Trading Update
15th Sep 20217:00 amRNSDirectorate Change
19th Aug 20217:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.